Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase - Recombinant Human elastase. The Company's lead product pipeline is TARA 002 for the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).
Number of employees : 29 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Opaleye Management, Inc. ||2,589,353||
|Jesse Shefferman ||797,705||
|Deerfield Management Company LP ||782,670||
|Rock Springs Capital Management LP ||693,542||
|Randall Marshall ||585,600||
|Ikarian Capital LLC ||479,995||
|OrbiMed Advisors Private Equity ||450,000||
|The Vanguard Group, Inc. ||433,154||
|Farallon Capital Management LLC ||425,000||
|Perceptive Advisors LLC ||421,641||
Sector Bio Therapeutic Drugs
Connections : Protara Therapeutics, Inc.